"January Surprise" Could Cut Bull Run Short, Says Banking Expert

According to one of America's most trusted banking experts – followed by names at Wells Fargo, UBS, and Barclays – the U.S. economy could look very different by January 20.

Click here to see Dan's warning (and possible solution) for America.

Zachariah Serber net worth and biography

Zachariah Serber Biography and Net Worth

Insider of Zymergen

Zach has extensive experience in industrial biotechnology, with 17 peer-reviewed publications and several patents across biomolecular discovery and microbial engineering. Formerly a director of biology at Amyris, he holds a PhD in Biophysics from University of California, San Francisco, an MSc in Neuroscience from the University of Edinburgh in the UK, and a BA in Biophysics from Columbia University.

What is Zachariah Serber's net worth?: The estimated net worth of Zachariah Serber is at least $6.21 million as of August 11th, 2022. Mr. Serber owns 2,554,953 shares of Zymergen stock worth more than $6,208,536 as of November 14th. This net worth approximation does not reflect any other investments that Mr. Serber may own. Learn More about Zachariah Serber's net worth.
How do I contact Zachariah Serber?: The corporate mailing address for Mr. Serber and other Zymergen executives is , , . Zymergen can also be reached via phone at 415-801-8073 and via email at [email protected]. Learn More on Zachariah Serber's contact information.
Has Zachariah Serber been buying or selling shares of Zymergen?: Zachariah Serber has not been actively trading shares of Zymergen during the last ninety days. Most recently, Zachariah Serber sold 5,435 shares of the business's stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $3.91, for a transaction totalling $21,250.85. Following the completion of the sale, the insider now directly owns 2,554,953 shares of the company's stock, valued at $9,989,866.23. Learn More on Zachariah Serber's trading history.
Who are Zymergen's active insiders?: Zymergen's insider roster includes Jay Flatley (CEO), Aaron Kimball (CTO), and Zachariah Serber (Insider). Learn More on Zymergen's active insiders.

Zachariah Serber Insider Trading History at Zymergen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/11/2022	Sell	5,435	$3.91	$21,250.85	2,554,953
8/2/2022	Sell	2,966	$2.61	$7,741.26	2,560,388
7/5/2022	Sell	2,797	$1.32	$3,692.04	2,563,354
5/2/2022	Sell	3,082	$1.79	$5,516.78	2,568,963
2/22/2022	Sell	1,424	$3.91	$5,567.84
2/14/2022	Sell	5,435	$4.00	$21,740.00
2/7/2022	Sell	5,435	$4.33	$23,533.55
1/31/2022	Sell	5,435	$5.03	$27,338.05
1/24/2022	Sell	21,730	$4.76	$103,434.80

Zachariah Serber Buying and Selling Activity at Zymergen

Zymergen Company Overview

Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. As of October 19, 2022, Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc.

Today's Range

Now: $2.43

$2.43

50 Day Range

MA: $2.52

$2.35

$3.14

2 Week Range

Now: $2.43

$1.10

$12.42

Volume

85 shs

Average Volume

1,229,575 shs

Market Capitalization

$253.58 million

P/E Ratio

N/A

Dividend Yield